Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...

Focus is turning to the development of peptide analogues of antibody-derived radiotherapeutics, according to Dr Dave Madge.

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

Exscientia detailed how its robotics lab in Oxfordshire, UK, is increasing productivity and efficiency in developing new ...

Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...

A smart beta exchange traded fund, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) debuted on 11/01/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are ...

The Food and Drug Administration in the US has just approved Cobenfy, which one researcher referred to as a "game changer" ...

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...

A Cleveland Clinic-led research collaboration between Timothy Chan, MD, PhD, Chair of Cleveland Clinic's Global Center for ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations early in treatment were linked to greater probability of sustained remission.

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...